UCB’s bimekizumab meets primary and secondary endpoints, beating Janssen’s Stelara in chronic plaque psoriasis
pharmafile | October 17, 2019 | News story | Research and Development | Stelara, UCB Pharma, bimekizumab, pharma, plaque psoriasis
UCB Pharma has announced new data from the first of three Phase 3 studies investigating the efficacy of its IL-17A and IL-17F inhibitor bimekizumab in the treatment of moderate-to-severe chronic plaque psoriasis in adult patients.
The findings showed that the therapy met both its co-primary endpoints of generating in patients an improvement of at least 90% on the Psoriasis Area and Severity Index and a score of clear or almost clear according to the Investigator Global Assessment (IGA) after 16 weeks
Additionally, bimekizumab proved itself superior to Janssen’s Stelara (ustekinumab) in reaching both these primary endpoints.
Bimekizumab is not currently approved by any regulators worldwide, but these results are likely to form the basis of such applications in future.
“These encouraging first results provide strong evidence that bimekizumab has the potential to raise the bar for achieving skin clearance rates for patients. Achieving clear skin is of critical importance in positively impacting the lives of psoriasis patients. Today’s announcement marks an important milestone in the extensive clinical development of bimekizumab,” commented Dr Mark Lebwohl, Lead Study Investigator, Waldman Professor of Dermatology and Chair of the Kimberly and Eric J Waldman Department of Dermatology at the Icahn School of Medicine at Mount Sinai in New York.
“Psoriasis affects all aspects of a patient’s life. We believe that bimekizumab has the potential to be a meaningful new treatment option for people living with psoriasis,” added Iris Loew-Friedrich, Head of Drug Development and Chief Medical Officer at UCB. “Today’s positive BE VIVID results are just the start. We look forward to sharing further findings from the bimekizumab clinical development programme in the coming months.”
Matt Fellows
Related Content
FDA approves IMIDEX’s AI-powered device VisiRad XR
The technological pharmaceutical company IMIDEX has been granted clearance from the US Food and Drug …
Artiva Biotherapeutics announces FDA clearance of IND for AlloNK and Rituximab combo
On 16 August 2023, the US Food and Drug Administration (FDA) officially cleared Artiva Biotherapeutics’ …
Novartis acquires Chinook Therapeutics for $3.5bn
Swiss pharmaceutical company Novartis has entered into an agreement and plan of merger with US-based …
